iForumRx.org
Who CARES? Getting to the Heart of Allopurinol and Febuxostat CV Outcomes

Who CARES? Getting to the Heart of Allopurinol and Febuxostat CV Outcomes

January 17, 2020

Should we target uric acid levels when working to reduce cardiovascular risk? Cardiovascular (CV) disease remains the leading cause of death with many contributing risk factors, including hyperuricemia. Evidence suggests an elevation in uric acid levels is associated with and can lead to worse outcomes for individuals with CV disease and heart failure.  The Cardiovascular Safety of Febuxostat and Allopurinol in Patients with Gout and Cardiovascular Morbidities (CARES) trial was conducted to evaluate whether febuxostat was noninferior to allopurinol with regard to CV events in patients with gout and CV disease.

Guest Authors:  Sophia Dietrich, PharmD and Michael W. Nagy, PharmD, BCACP

Music by Good Talk

Inflammatory Statements about Cardiovascular Risk Reduction: The CANTOS Trial

Inflammatory Statements about Cardiovascular Risk Reduction: The CANTOS Trial

January 5, 2018

We’ve all seen and used the American College of Cardiology 10-year atherosclerotic cardiovascular disease (ASCVD) risk calculator. There are several modifiable risk factors such as blood pressure, cholesterol, and smoking status that, if addressed, can lower ASCVD risk. But are there other modifiable risk factors that we are failing to account for and might be able to address? New evidence suggests systemic inflammation may be one.

Guest Authors:  Ian Hatlee, Pharm.D and Scott Pearson, Pharm.D.

Music by Good Talk